A Study of Pemetrexed in the Treatment of Patients With Advanced Metastatic Cancer of the Liver

Phase II Study of Single-Agent Alimta in the Treatment of Patients With Advanced and Metastatic Hepatoma

This study is to assess the response rate, toxicity, time-to-event efficacy, and potential markers of pemetrexed in patients with liver cancer.

Inclusion Criteria:

• Diagnosis of cancer of the liver which is metastatic or locally recurrent and not amendable to curative therapy.
• Patient must have measurable disease
• Patient may have received prior arterial chemoembolization, completed 8 weeks prior to study enrollment, but no other previous chemotherapy
• Prior radiation is permitted, but must be completed at least 2 weeks prior to study enrollment.
• Prior central nervous system metastases are acceptable if the patient has received radiation ot the brain, is not on steroids, and does not have related symptoms.

Exclusion Criteria:

• Patients who have had prior therapy with Pemetrexed.
• Patients with a history of other invasive malignancies, with the exception of non-melanoma skin cancer, are excluded if there is any evidence of other malignancy being present within the last five years. Patients are also excluded if their previous cancer treatment contraindicates this protocol therapy.
• Patients who have received radiation to more than 25% of marrow